Tempus Gains FDA Clearance for RNA-Based Diagnostic, Expanding Role in Precision Oncology
FDA Clearance Bolsters Tempus' Offering in Precision Medicine
Tempus AI, Inc. (NASDAQ:TEM) has announced it has received U.S. FDA 510(k) clearance for its Tempus xR IVD device, a next-generation sequencing (NGS) in vitro diagnostic tool using RNA analysis. This milestone grants Tempus the ability to offer xR IVD as a solution for life sciences partners supporting drug development programs and clinical trials.
RNA Sequencing: Enhanced Fusion Detection and Personalized Insights
RNA sequencing captures a broader spectrum of biological information compared to DNA analysis alone, providing deeper insights into disease mechanisms and improving detection of genetic rearrangements. According to the company, the Tempus xR IVD utilizes targeted, high-throughput hybridization-based capture technology, focusing on two gene rearrangements in formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from patients with solid malignant neoplasms.
By integrating RNA-based information, Tempus believes it can help researchers and pharmaceutical partners better identify which patients may respond to specific therapies and enable more efficient clinical trial designs—an increasingly valuable capability as RNA biomarkers are incorporated into new cancer treatments.
Life Science Partners Gain New Research and Development Tool
With the FDA's 510(k) clearance, Tempus xR IVD is positioned as a key asset for pharmaceutical collaborators seeking robust and regulatory-cleared diagnostic support in oncology research. Kate Sasser, PhD, Tempus’ Chief Scientific Officer, noted that “this FDA clearance further demonstrates the promise of RNA sequencing and opens up new opportunities for us with our biopharma customers.”
The device is intended to be used by qualified healthcare professionals following established oncology guidelines and is not prescriptive or conclusive for any specific therapeutic product. Its primary value lies in supporting discovery, development, and delivery of new therapeutics with actionable insights from RNA data.
| Device Name | Tempus xR IVD |
|---|---|
| Technology | Targeted hybridization-based RNA NGS |
| Application | Detection of gene rearrangements in FFPE tumor tissue |
| Use Case | Oncology research, drug development support |
| Regulatory Status | FDA 510(k) cleared |
Tempus' Expanding Portfolio Supports Therapeutic Innovation
The clearance reinforces Tempus' strategy of offering a “one-stop shop” for precision medicine solutions in oncology. Beyond the new RNA-based assay, Tempus provides a range of intelligent diagnostics and maintains one of the largest libraries of multimodal health data. These resources underpin its AI-driven precision medicine offerings and its support for life science research.
Looking ahead, Tempus expects RNA biomarkers will play an increasingly central role in both therapeutic development and personalized patient care—making the newly cleared assay a cornerstone for future collaborations and clinical advances.
Key Takeaway: Clearance Strengthens Position for Future Collaborations
For stakeholders in precision medicine and oncology, the FDA’s green light for Tempus xR IVD signals growing adoption of RNA analytics in both research and real-world care. Life science companies and clinicians tracking the evolution of biomarker-driven diagnostics will want to monitor how Tempus leverages its xR IVD to fuel new research, partnership, and drug development opportunities in the months ahead.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI